English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Controlled-release (CR) pharmaceutical formulations offer several advantages   over the conventional, immediate release dosage forms of the same drug,   including reduced dosing frequency, decreased incidence and/or intensity of   adverse effects, greater selectivity of pharmacological activity, reduced   drug plasma fluctuation, and better compliance. After a drug product has been   registered, and is already on market, minor changes in formulation might be   needed. At the same time, the product has to remain effective and safe for   patients that could be confirmed via plasma drug concentrations and   pharmacokinetic characteristics. It is challenging to predict human   absorption and pharmacokinetic characteristics of a drug based on the in   vitro dissolution test and the animal pharmacokinetic data. Therefore, the   objective of this study was to establish correlation of the pharmacokinetic   parameters of carbamazepine (CBZ) CR tablet formulation between the rabbit   and the human model, and to establish in vitro in vivo correlation (IVIVC)   based on the predicted fractions of absorbed CBZ. Although differences in   mean plasma concentration profiles were notified, the data concerning the   predicted fraction of drug absorbed were almost superimposable. Accordingly,   it can be concluded that rabbits may be representative as an in vivo model   for predicting the pharmacokinetics of the CR formulation of CBZ in humans

Predicting absorption and pharmacokinetic profile of carbamazepine from controlled-release tablet formulation in humans using rabbit model